Therapeutic Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-11 Ameliorates Cardiac Fibrosis After Myocardial Infarction

Masanori Obana, MS; Makiko Maeda, PhD; Koji Takeda, MD; Akiko Hayama, MS; Tomomi Mohri, PhD; Tomomi Yamashita, BS; Yoshikazu Nakaoka, MD, PhD; Issei Komuro, MD, PhD; Kiyoshi Takeda, MD, PhD; Goro Matsumiya, MD, PhD; Junichi Azuma, MD; Yasushi Fujio, MD, PhD

Background—Glycoprotein 130 is the common receptor subunit for the interleukin (IL)-6 cytokine family. Previously, we reported that pretreatment of IL-11, an IL-6 family cytokine, activates the glycoprotein 130 signaling pathway in cardiomyocytes and prevents ischemia/reperfusion injury in vivo; however, its long-term effects on cardiac remodeling after myocardial infarction (MI) remain to be elucidated.

Methods and Results—MI was generated by ligating the left coronary artery in C57BL/6 mice. Real-time reverse transcription polymerase chain reaction analyses showed that IL-11 mRNA was remarkably upregulated in the hearts exposed to MI. Intravenous injection of IL-11 activated signal transducer and activator of transcription 3 (STAT3), a downstream signaling molecule of glycoprotein 130, in cardiomyocytes in vivo, suggesting that cardiac myocytes are target cells of IL-11 in the hearts. Twenty-four hours after coronary ligation, IL-11 was administered intravenously, followed by consecutive administration every 24 hours for 4 days. IL-11 treatment reduced fibrosis area 14 days after MI, attenuating cardiac dysfunction. Consistent with a previous report that STAT3 exhibits antiapoptotic and angiogenic activity in the heart, IL-11 treatment prevented apoptotic cell death of the bordering myocardium adjacent to the infarct zone and increased capillary density at the border zone. Importantly, cardiac-specific ablation of STAT3 abrogated IL-11–mediated attenuation of fibrosis and was associated with left ventricular enlargement. Moreover, with the use of cardiac-specific transgenic mice expressing constitutively active STAT3, cardiac STAT3 activation was shown to be sufficient to prevent adverse cardiac remodeling.

Conclusions—IL-11 attenuated cardiac fibrosis after MI through STAT3. Activation of the IL-11/glycoprotein 130/STAT3 axis may be a novel therapeutic strategy against cardiovascular diseases. (Circulation. 2010;121:684-691.)

Key Words: interleukins | myocardial infarction | remodeling | signal transduction

After myocardial injury, various kinds of neurohumoral factors and cytokines modulate cardiac remodeling. Among them, leukemia inhibitory factor (LIF) and cardiotoxin-1, which belong to the interleukin (IL)-6 family, play important roles in cardioprotection.1,2 LIF and cardiotoxin-1 are secreted from cardiomyocytes in response to pathological stress.3,5 These cytokines bind and activate LIF receptor in cardiomyocytes.6 Activated LIF receptor makes a dimer with glycoprotein 130 (gp130), followed by activation of signal transducer and activator of transcription 3 (STAT3).7 STAT3 activation promotes cardiomyocyte survival and vascular formation in the heart.8–10 Thus, cardiac activation of the gp130/STAT3 system may be a potential therapeutic strategy against cardiovascular diseases; however, therapies targeting gp130 have not been proposed.

Clinical Perspective on p 691

The difficulty in therapeutic activation of gp130 is derived from its receptor system. Gp130 is expressed ubiquitously as the common receptor subunit of IL-6 family cytokines.11 IL-6 family cytokines bind their specific receptor α subunits, followed by activation of a common gp130 receptor. Pleiotropic effects of IL-6 family cytokines are explained by the differential expression of receptor α subunits. Most members of the IL-6 family, whose receptor α subunits are expressed abundantly in inflammatory cells, would evoke severe in-
flammation\textsuperscript{12} as a serious adverse event if administered systemically. Therefore, to achieve clinical use of IL-6 family cytokines, the cytokine that induces only a tolerable level of inflammation should be selected.

IL-11 is a hematopoietic IL-6 family cytokine with pleiotropic effects. IL-11 exhibits thrombopoietic activity, and recombinant human IL-11 is used clinically for thrombocytopenia.\textsuperscript{13} In contrast to other IL-6 family members, IL-11 protects epithelial cells of the intestine from tissue damage, suggesting its cytoprotective property.\textsuperscript{15} Recently, we demonstrated that the IL-11 receptor is expressed in cardiomyocytes and that pretreatment of IL-11 confers resistance to ischemia/reperfusion injury in a murine model as a preconditioning effect.\textsuperscript{16} When the limited level of clinical adverse effects of recombinant human IL-11 is considered,\textsuperscript{13} IL-11 may be a candidate to be available clinically as cardiac gp130-targeting therapy against heart diseases.

In this study, we investigated the long-term effects of IL-11 treatment after myocardial infarction (MI). In addition, we report that IL-11 treatment prevents adverse cardiac remodeling through the STAT3 pathway.

**Methods**

**Animal Care**

The care of all animals was in compliance with the Osaka University animal care guidelines. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (National Institutes of Health publication No. 85-23, revised 1996).

**Coronary Artery Ligation and IL-11 Treatment**

MI was generated by coronary artery ligation according to the previous report with minor modifications. Briefly, C57BL/6 mice (8 to 10 weeks old; Japan SLC) were anesthetized and ventilated with 80% oxygen containing 1.5% isoflurane (Merek). After left-side thoracotomy, the left coronary artery was ligated with 7-0 silk sutures. Infarction was confirmed by discoloration of the ventricle and ST-T changes on ECG: The chest and skin were closed with 5-0 silk sutures. In preliminary experiments, we confirmed that the operation reproducibly generates infarction with the initial area at risk 20% to 25% per left ventricular (LV) area, as analyzed by Evans blue exclusion assays.\textsuperscript{16} Sham-operated mice were subjected to similar surgery, except that no ligature was placed. Twenty-four hours after MI operation, mice were randomly assigned to 2 groups: the IL-11 group and control group. In the IL-11 group, recombinant human IL-11 (Peprotech) was administered intravenously for 5 days consecutively; the control group received the same volume of saline. The hearts were excised rapidly and placed in ice-cold modified Tyrode's solution (140 mmol/L NaCl, 4.5 mmol/L KCl, 1.8 mmol/L CaCl\textsubscript{2}, 0.45 mmol/L MgCl\textsubscript{2}, 0.33 mmol/L NaH\textsubscript{2}PO\textsubscript{4}, 5.5 mmol/L glucose, 5 mmol/L HEPES (pH 7.4)). The aorta was cannulated and retrogradely perfused at a constant pressure of 100 mm Hg with Tyrode's solution bubbled with 80% oxygen at 37°C. The experiments were performed at 37°C by immersing the heart in Tyrode's solution in a water-jacketed chamber. The hearts were paced at 420 bpm. The fluid-filled balloon was inserted into the LV to monitor cardiac function. The balloon was attached to a pressure transducer, which was connected to a 4S PowerLab (AD Instruments). LV developed pressure and ±dP/dt were measured.

**Immunofluorescent Microscopic Analyses**

The hearts were harvested 15 minutes after intravenous injection of IL-11, and the frozen sections were prepared. The sections were stained with anti-p-STAT3 and anti-sarcomeric α-actinin (Sigma) antibodies. Alexa Fluor 488-conjugated goat anti-rabbit IgG (Molecular Probes) and Alexa Fluor 546-conjugated goat anti-mouse IgG (Molecular Probes) were used as secondary antibodies. Nuclei were also stained with Hoechst 33258.

Apoptotic cell death was detected by a terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling (TUNEL) staining with an in situ Apoptosis Detection Kit (TaKaRa). The section was costained with anti-sarcomeric α-actinin antibody to identify the cardiac myocytes. For quantitative analyses, apoptotic myocytes were counted in number by a researcher who was blinded to the assay conditions.

**Immunohistochemical Analyses**

The frozen sections were prepared as described above. Capillary density was examined by immunohistochemical staining with the use of the Vectastain ABC kit (Vector Laboratories) with anti-CD31 antibody (BD Biosciences, San Jose, Calif). To estimate capillary...
density quantitatively, the number of capillaries was counted by a researcher who was blinded to the assay conditions.

**Conditional Ablation of the STAT3 Gene in Cardiomyocytes of Adult Murine Heart**

The transgenic mice in which Cre recombinase fused to the mutated estrogen receptor domains (MerCreMer) were driven by the cardiomyocyte-specific α-myosin heavy chain (α-MHC) promoter, designated as α-MHC-MerCreMer mice, were a gift from Dr Molkentin. We crossed the α-MHC-MerCreMer mice with mice that carried floxed STAT3 alleles (STAT3<sup>flox/flox</sup>)<sup>19</sup> and produced α-MHC-MerCreMer/STAT3<sup>flox/flox</sup> mutant mice. To induce Cre-mediated recombination, mice were treated with 20 mg/kg tamoxifen (Sigma, St Louis, Mo) by intraperitoneal injection once per day for 5 consecutive days. Five days after the last treatment, the level of STAT3 expression decreased dramatically, and the mutant mice underwent MI as described above.

**Cardiac-Specific Transgenic Mice Expressing Constitutively Active STAT3**

Generation of cardiac-specific transgenic mice expressing constitutively active STAT3 was described previously.<sup>9</sup>

**Results**

**IL-11 Is a Cardiac Cytokine That Activates STAT3 in Cardiomyocytes In Vivo**

We analyzed the expression of IL-11 mRNA in hearts at various time points after MI. Hearts were separated into infarct area and remote area, and the expression of IL-11 mRNA was measured by real-time RT-PCR (Figure 1A). The expression of IL-11 transcript was elevated, with its peak at 1 day after MI, and was gradually reduced at both infarct and remote areas. In the infarct area, the enhanced expression of IL-11 was sustained for 14 days. These data indicate that IL-11 is produced in the heart during cardiac remodeling after MI.

Next, we examined whether intravenous administration of IL-11 stimulates STAT3 in hearts by immunoblot analysis with anti-p-STAT3 antibody (Figure 1B). STAT3 phosphorylation was induced rapidly and reduced to the basal level within 180 minutes after IL-11 injection. IL-11 activated STAT3 in the heart in a dose-dependent manner (Figure 1C). IL-11 stimulation of p-STAT3 was localized mainly in cardiomyocyte nuclei of postinfarct hearts, and IL-11 treatment increased the frequency of p-STAT3–positive cardiac myocytes (Figure 1C).

**IL-11 Administration Attenuates Cardiac Remodeling After MI**

To examine the effects of IL-11 on adverse cardiac remodeling, IL-11 was administered to the mice after MI operation, and cardiac fibrosis was histologically estimated at day 14 after MI (Figure 2). Both fibrotic circumference and fibrotic area were reduced by IL-11 in a dose-dependent manner (Figures 2B and C). Treatment of IL-11 at 8 μg/kg achieved a submaximal reduction in fibrotic circumference by 28.9% (PBS, 39.4 ± 33.1%; IL-11, 26.6 ± 7.4%). Interestingly, IL-11–treated hearts showed an increase in infarct wall thickness compared with PBS-treated hearts (Figure 2D).
examine the effects of IL-11 on LV hypertrophy, we analyzed expression of α-skeletal muscle actin mRNA, a well-known marker of LV hypertrophy (Figure III in the online-only Data Supplement). IL-11 treatment showed a tendency to reduce α-skeletal muscle actin expression, although its reduction was not statistically significant.

To clarify whether IL-11 prevents cardiac dysfunction after MI, we measured LV developed pressure and ±dP/dt by a Langendorff apparatus. As acute myocardial damage, MI rapidly impaired LV developed pressure and ±dP/dt at day 1 (Table I in the online-only Data Supplement) before IL-11 administration was started. Because IL-11 treatment attenuated cardiac fibrosis that occurred during the following 2 weeks, we examined the effects of IL-11 on cardiac function 2 weeks after MI (Table). IL-11 treatment ameliorated chronic cardiac dysfunction in a dose-dependent manner compared with the PBS-treated group. Consistent with the attenuation of fibrosis, treatment of IL-11 at a dose of 8 μg/kg submaximally prevented cardiac dysfunction. Thus, further experiments were performed with the use of IL-11 at a dose of 8 μg/kg.

We also confirmed the inhibitory effects of IL-11 on adverse cardiac remodeling 28 days after MI. IL-11 treatment prevented cardiac fibrosis and preserved cardiac function (Figure IV in the online-only Data Supplement).

To examine whether IL-11 reduces infarct size, infarct size was measured by Evans blue exclusion 2 days after MI. There was no significant difference in infarct size (PBS, 23.0±7.1%; IL-11 [8 μg/kg], 22.0±4.3%; n=4 mice for each group).

**IL-11 Treatment Exhibits Antiapoptotic and Proangiogenic Activity in the Heart**

Granulocyte colony-stimulating factor (G-CSF) was reported to prevent cardiac remodeling after MI, accompanied by antiapoptotic and proangiogenic effects through STAT3.20 Because IL-11 activated STAT3 in cardiomyocytes (Figure 1), we examined the effects of IL-11 on cardiomyocyte survival and vascular formation in postinfarct myocardium.

To evaluate the antiapoptotic effects of IL-11, TUNEL staining was performed (Figure 3A). TUNEL-positive cardiomyocytes were detected mainly at the border zone, adjacent to the ischemic area, at both day 2 and day 4 after MI. Importantly, IL-11 treatment significantly reduced the number of apoptotic cardiomyocytes compared with the PBS group. To further confirm the cytoprotective effects, the cleavage of caspase 3 was examined by immunoblot analyses with cleaved caspase 3-specific antibody (Figure 3B). Compared with PBS treatment, IL-11 significantly reduced the band intensity for cleaved caspase 3. To address the antiapoptotic pathways downstream of the IL-11 signal, we examined the expression of cell survival proteins (Figure 3C). Immunoblot analysis revealed that Bcl-2 and survivin proteins, both of which have been characterized as downstream targets of STAT3,21–23 were increased in the IL-11 group (Bcl-2, 1.9-fold; survivin, 1.5-fold).

Because activation of STAT3 mediated vascular formation during cardiac remodeling,20,24 capillary density was immu-

---

**Table. Effects of IL-11 on Cardiac Function at Day 14 After MI**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>PBS</th>
<th>3</th>
<th>8</th>
<th>20</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVDP, mm Hg</td>
<td>32.4±4.4</td>
<td>34.9±6.3</td>
<td>45.3±6.3</td>
<td>44.3±13.5*</td>
</tr>
<tr>
<td>±dP/dt, mm Hg/s</td>
<td>884±113</td>
<td>958±162</td>
<td>1210±148*</td>
<td>1243±324*</td>
</tr>
<tr>
<td>−dP/dt, mm Hg/s</td>
<td>−713±93</td>
<td>−737±176</td>
<td>−1022±210*</td>
<td>−1043±326*</td>
</tr>
</tbody>
</table>

Data are mean±SD (n=8 mice for PBS; n=9 mice for 3 μg/kg; n=9 mice for 8 μg/kg; n=8 mice for 20 μg/kg). LVDP indicates LV developed pressure.

*P<0.05 vs PBS by 1-way ANOVA followed by Bonferroni test.
Activation of STAT3 Is Necessary and Sufficient for IL-11–Mediated Prevention of Cardiac Remodeling

To assess the importance of cardiac STAT3 activation in IL-11–mediated attenuation of adverse remodeling, we generated cardiac-specific conditional STAT3-deficient mice (STAT3 CKO mice) by establishing α-MHC-MerCreMer mice on STAT3^{floxed/floxed} background (Figure 5A). The ablation of the STAT3 gene did not induce notable histological alterations at day 14 after sham operation. IL-11 treatment ameliorated postinfarct fibrosis in α-MHC-MerCreMer mice on STAT3^{wild/wild} background after MI (Figure V in the online-only Data Supplement), as in the case with nontransgenic mice (Figure 2). Importantly, IL-11–mediated prevention against adverse cardiac remodeling was abrogated in STAT3 CKO mice (Figure 5C and 5D). Interestingly, enlargement of LVs was observed in STAT3 CKO mice compared with wild-type mice exposed to MI without IL-11 treatment (18.02±3.20 mm [n=6] versus 15.08±1.81 mm [n=8]; P<0.05), probably because STAT3 is endogenously activated after MI, even without IL-11 treatment (Figures II and VI in the online-only Data Supplement), and contributes to the prevention of adverse cardiac remodeling. Consistently, we also confirmed that IL-11–mediated attenuation of cardiac dysfunction was canceled in STAT3 CKO mice (Figure VII in the online-only Data Supplement). Moreover, the increase in capillary density, which was observed in response to IL-11 in the mice with STAT3^{wild/wild} background, was abrogated by STAT3 gene ablation (Figure VIII in the online-only Data Supplement). These data indicate that STAT3 is required for IL-11–mediated amelioration of adverse cardiac remodeling after MI.

To reinforce the importance of STAT3 in cardioprotection, transgenic hearts expressing constitutively active STAT3 (caSTAT3) were exposed to MI, and cardiac fibrosis was estimated. In caSTAT3 transgenic hearts, cardiac fibrosis was reduced by 47% compared with nontransgenic littermates (wild-type) (Figure 6). Moreover, similar to IL-11–treated hearts, caSTAT3 transgenic hearts showed an increase in fibrotic wall thickness. Importantly, cardiac dysfunction was ameliorated in caSTAT3 transgenic mice compared with wild-type mice (Figure IX in the online-only Data Supplement). Therefore, activation of STAT3 in cardiomyocytes was sufficient to suppress cardiac remodeling after MI.
Discussion

In this study, we examined the effects of IL-11 treatment on adverse cardiac remodeling after MI. IL-11 activated STAT3 in cardiomyocytes in vivo. IL-11 ameliorated cardiac fibrosis and attenuated cardiac dysfunction after MI. IL-11 reduced the number of apoptotic myocytes, and IL-11–treated hearts showed an increase in capillary density. Importantly, the preventive effects of IL-11 against adverse remodeling were suppressed in cardiac-specific STAT3-deficient mice. Moreover, cardiac STAT3 activation was sufficient to suppress adverse remodeling. These findings suggest that IL-11 treatment is a promising strategy against adverse cardiac remodeling after MI.

Previously, G-CSF and erythropoietin were reported to exhibit preventive effects against postinfarct fibrosis20,25,26; however, a large difference in signaling pathways exists among these cytokines. IL-11 rapidly activates STAT3 in cardiomyocytes at a lower concentration than G-CSF, suggesting that IL-11 is a more potent activator of STAT3. Akt, another cytoprotective signal transducer, is activated by G-CSF and erythropoietin in cardiomyocytes27–29 and to a lesser extent by IL-11 (data not shown). Moreover, G-CSF confers resistance to ischemia/reperfusion through endothelial Akt activation30 and IL-11 through cardiomyocyte activation of STAT3.16 Thus, IL-11 transduces cardioprotective signals via pathways that are distinct from G-CSF or erythropoietin.

IL-11 belongs to the IL-6 cytokine family, which uses gp130 as its common receptor. Interestingly, LIF, a member of the IL-6 cytokine family, has been reported to enhance survival of cardiomyocytes, with mobilization of bone marrow cells to the heart.1 Similarly, G-CSF stimulates the homing of bone marrow cells to the heart, leading to regeneration of the injured heart.31 These studies propose that bone marrow cells may contribute to cardiac repair in response to cytokine stimuli. In our experiments, IL-11 failed to show cardioprotective effects in cardiomyocyte-specific STAT3-deficient mice. Therefore, cardiomyocytes are important components in the action of IL-11, and STAT3 activation in cardiomyocytes is a critical factor for IL-11–mediated prevention of adverse cardiac remodeling, although we cannot exclude the possibility that bone marrow cell
mobilization is regulated by cardiac STAT3 through some paracrine systems.

Previously, we reported that IL-11 shows cytoprotective effects through STAT3 and prevents ischemia/reperfusion injury in the heart. IL-11 reduced cardiomyocyte apoptosis after MI consistently in this study. In addition to cell-autonomous cytoprotection, we have demonstrated that IL-11 promoted vessel growth in the heart. Importantly, the enhancement of capillary density by IL-11 was not observed in cardiac-specific STAT3-deficient mice. Taken together with previous reports that cardiac activation of STAT3 promotes vascular formation in the heart, STAT3 is a critical regulator of the interaction between myocardium and endothelium. Interestingly, IL-11-mediated enhancement of vascular formation was closely associated with improvement of cardiomyocyte viability. Similarly, it was reported recently that cardiac production of angiogenic growth factors was impaired under decompensatory conditions during cardiac remodeling and that angiogenesis was critical to prevent onset of heart failure in response to pathological stress. Collectively, this suggests that IL-11 mediates cardiomyocyte survival and capillary growth in an interdependent manner and that these signals are coordinated by STAT3.

IL-11 exerted preventive effects against adverse cardiac remodeling after MI at almost the same level as G-CSF, whose clinical use was reported to be at least partially beneficial in cardiovascular diseases. Thus, IL-11 treatment may be proposed as a novel cytokine therapy. Although one of the most serious adverse effects of cytokine therapy is inflammation, IL-11 is known to be an anti-inflammatory cytokine. Indeed, IL-11 significantly suppressed expression of proinflammatory cytokines, such as IL-6 and tumor necrosis factor-α, in postinfarct myocardium (Figure X in the online-only Data Supplement), which provides evidence supporting its safety.

In summary, IL-11 transduced cardioprotective signals through STAT3 and suppressed adverse cardiac remodeling after MI. The IL-11/gp130/STAT3 axis may be a novel therapeutic target against cardiovascular diseases.

Acknowledgments

We thank Yasuko Murao for excellent secretarial work.

Sources of Funding

This study was supported by a grant-in-aid for scientific research from the Japan Society for the Promotion of Science, Mitsubishi Pharma Research Foundation, Takeda Science Foundation, Osaka Foundation for Promotion of Clinical Immunology, and a grant-in-aid from Knowledge Cluster Initiative (Second Stage) of the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Disclosures

None.

References


16. Obana et al IL-11 as a Novel Cardioprotective Cytokine 691


Therapeutic Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-11 Ameliorates Cardiac Fibrosis After Myocardial Infarction
Masanori Obana, Makiko Maeda, Koji Takeda, Akiko Hayama, Tomomi Mohri, Tomomi Yamashita, Yoshikazu Nakaoka, Issei Komuro, Kiyoshi Takeda, Goro Matsumiya, Junichi Azuma and Yasushi Fujio

Circulation. published online January 25, 2010;
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/early/2010/01/25/CIRCULATIONAHA.109.893677.citation

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2010/01/26/CIRCULATIONAHA.109.893677.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/
SUPPLEMENTAL MATERIAL
Supplementary Materials and Methods

Real time RT-PCR
The expression of α-skeletal muscle actin mRNA was quantified by real time RT-PCR using the ABI-PRISM® 7700 sequence detection system with SYBR green system. The primers for α-skeletal muscle actin are as follows;
α-skeletal muscle actin forward: 5’-AGGGCCAGAGTCAGAGCAG -3’,
α-skeletal muscle actin reverse: 5’-CCGTTGTCACACACAAGA -3’.
The expression of IL-6 or TNF-α mRNA was quantified by real time RT-PCR using the ABI-PRISM® 7700 sequence detection system with TaqMan Assay on Demand Reagents (PE Applied Biosystems Inc.).

Supplementary Figure Legends

Supplementary Figure 1
IL-11 activated STAT3 in murine hearts in a dose-dependent manner.
The various concentrations of IL-11 were intravenously administered to mice. Fifteen minutes after injection, mice were sacrificed. The lysates were prepared from hearts and immunoblotted with anti-phospho-specific STAT3 (p-STAT3) antibody. Blots were reprobed with anti-STAT3 antibody. Experiments were repeated three times with similar results.

Supplementary Figure 2
IL-11 activated STAT3 in the cardiomyocytes at day 1 after MI.
IL-11 (8 µg/kg) or PBS was intravenously administered in mice at day 1 after MI. Fifteen minutes after injection, the hearts were harvested and frozen sections were prepared. The sections were co-stained with anti-phospho-specific STAT3 (p-STAT3) and anti-sarcomeric α-actinin antibodies. Hoechst 33258 staining was also performed to identify the nuclei. The images shown are representative of 15 obtained from 3 mice (5 fields from each mouse). Arrowheads show the p-STAT3-positive nuclei. Bar, 50 µm.

Supplementary Figure 3
The effect of IL-11 on the expression of α-skeletal muscle actin after MI.
Total RNA was prepared from infarct (I) or remote (R) area of hearts after MI and real time RT-PCR was performed for α-skeletal muscle actin. The expression of α-skeletal muscle actin
was normalized with that of GAPDH. Data are shown as mean ± S.D. (n=5 mice for each group).

**Supplementary Figure 4**

**IL-11 attenuated the cardiac remodeling at day 28 after MI.**

Mice were exposed to MI operation, followed by the treatment of IL-11 for 5 days. PBS was used as control. Heart sections were prepared 28 days after MI and stained with Masson’s Trichrome method to determine fibrosis. The ratio of fibrotic circumference to LV circumference was quantitatively estimated. LVDP and ±dp/dt were measured by a Langendorff apparatus at day 28 after MI. Data are shown as mean ± S.D. (n=4 mice, for PBS; n=7 mice, for IL-11). *P<0.05 vs. PBS, by unpaired t test.

**Supplementary Figure 5**

**IL-11 treatment reduced the cardiac fibrosis in α-MHC-MerCreMer mice on STAT3 wild/wild background after MI.**

MI was generated in α-MHC-MerCreMer mice on STAT3 wild/wild background, followed by IL-11 treatment for 5 days. Heart sections (3 sections from each mouse) were prepared 14 days after MI and stained with Masson’s Trichrome method to determine fibrosis. (A) The images are representative of 18 obtained from 6 mice. Bar, 1 mm. (B) The ratio of fibrotic circumference to LV circumference was quantitatively estimated. Data are shown as mean ± S.D. (n=6 mice for each group). *P<0.01 vs. PBS, by unpaired t test.

**Supplementary Figure 6**

**Cardiac activation of STAT3 was sustained during cardiac remodeling after MI in mice.**

Mice were exposed to MI operation and the hearts were harvested at the indicated time point. The lysates were prepared from hearts and immunoblotted with anti-phospho-specific STAT3 (p-STAT3) antibody. Blots were reprobed with anti-STAT3 antibody.

**Supplementary Figure 7**

**STAT3 was required for IL-11-mediated amelioration of cardiac dysfunction after MI.**

After tamoxifen treatment, MI was generated in α-MHC-MerCreMer/STAT3^floxflox_ (floxflox, n=4) or α-MHC-MerCreMer/STAT3^wild/wild_ (wild/wild, n=4) mice, followed by the administration of IL-11. At day 14 after MI, LVDP and ±dp/dt were measured by a Langendorff apparatus. Data are shown as mean ± S.D. *P<0.05 vs. α-MHC-MerCreMer/STAT3^wild/wild_, by unpaired t test.
**Supplementary Figure 8**

The enhancement of capillary density by IL-11 was not observed in cardiac-specific STAT3-deficient mice.

After tamoxifen treatment, MI was generated in α-MHC-MerCreMer/STAT3\(^{\text{flox/flox}}\) or α-MHC-MerCreMer/STAT3\(^{\text{wild/wild}}\) mice, followed by the administration of IL-11. Heart sections were prepared 14 days after MI and stained with anti-CD31 antibody, to detect capillary endothelial cells. The CD31-positive capillary density was quantitatively estimated. Ten visual fields were randomly selected. Data are shown as mean ± S.D. (n=6 mice for each group). *\(P<0.01\) vs. STAT3\(^{\text{wild/wild}}\) without IL-11 treatment. #\(P<0.01\) vs. STAT3\(^{\text{flox/flox}}\) with IL-11 treatment, by one-way ANOVA followed by Bonferroni test.

**Supplementary Figure 9**

Activation of STAT3 in cardiomyocytes was sufficient for amelioration of cardiac dysfunction.

Cardiac-specific transgenic mice expressing constitutively active STAT3 (caSTAT3) or wild-type mice were exposed to MI. At day 14 after MI, LVDP and ±dp/dt were measured by a Langendorff apparatus. Data are shown as mean ± S.D. (n=5 mice for each group). *\(P<0.05\) vs. wild-type, by unpaired t test.

**Supplementary Figure 10**

IL-11 suppressed the inflammatory reaction in post-infarct myocardium.

Total RNA was prepared from infarct hearts at day 4 after MI or sham operation. The expression level of IL-6 or TNF-α mRNA was measured by real time RT-PCR methods and normalized with that of GAPDH. The cytokine level was expressed as fold induction of that in non-infarct hearts. Data are shown as mean ± S.D. (n=4 mice for each group). *\(P<0.05\) vs. sham, #\(P<0.05\) vs. PBS, by one-way ANOVA followed by Bonferroni test.
## Supplementary Table 1. Cardiac function at day 1 after MI before IL-11 treatment.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Baseline</th>
<th>One day post MI</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVDP (mmHg)</td>
<td>83.0±8.8</td>
<td>53.9±12.6*</td>
</tr>
<tr>
<td>+dp/dt (mmHg/s)</td>
<td>2321±390</td>
<td>1485±316*</td>
</tr>
<tr>
<td>-dp/dt (mmHg/s)</td>
<td>-2030±353</td>
<td>-1242±290*</td>
</tr>
</tbody>
</table>

Data were shown as mean ± S.D. (n=7 mice, for baseline; n=7 mice, one day post MI).
*P<0.01 vs. Baseline, by unpaired t test.

## Supplementary Table 2. The dependency of IL-11 therapy on the treatment timing.

<table>
<thead>
<tr>
<th></th>
<th>Fibrotic area / LV area (%)</th>
<th>Capillaries (/mm²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>42.6±13.1</td>
<td>2052±118</td>
</tr>
<tr>
<td>IL-11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>d1-d3</td>
<td>26.4±8.0*</td>
<td>2304±179*</td>
</tr>
<tr>
<td>d3-d5</td>
<td>34.8±9.0</td>
<td>2153±232</td>
</tr>
</tbody>
</table>

Data were shown as mean ± S.D. (n=8 mice, for PBS; n=9 mice, for d1-d3; n=9 mice, for d3-d5). *P<0.05 vs. PBS, by one-way ANOVA followed by Bonferroni test.
<table>
<thead>
<tr>
<th>Dose (µg/kg)</th>
<th>0</th>
<th>3</th>
<th>8</th>
<th>20</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-11</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-STAT3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>total STAT3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Supplementary Figure 1
Supplementary Figure 2
Supplementary Figure 3

α-skeletal muscle actin / GAPDH (fold of normal mice)

<table>
<thead>
<tr>
<th></th>
<th>PBS</th>
<th>IL-11</th>
<th>PBS</th>
<th>IL-11</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Supplementary Figure 4
Supplementary Figure 5
<table>
<thead>
<tr>
<th>non-MI</th>
<th>1</th>
<th>4</th>
<th>7</th>
<th>14</th>
</tr>
</thead>
<tbody>
<tr>
<td>p-STAT3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>total STAT3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Supplementary Figure 7
Supplementary Figure 8
Supplementary Figure 9
Supplementary Figure 10